169 related articles for article (PubMed ID: 38331776)
21. Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis.
Xiao L; Yang S; Hao J; Yuan X; Luo W; Jiang L; Hu Y; Fu Z; Zhang Y; Zou C
Cancer Lett; 2015 Apr; 359(1):148-54. PubMed ID: 25597785
[TBL] [Abstract][Full Text] [Related]
22. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
[TBL] [Abstract][Full Text] [Related]
23. Predictors for the efficacy of Endostar combined with neoadjuvant chemotherapy for stage IIIA (N2) NSCLC.
Zhao X; Wen X; Wei W; Su Y; You J; Gong L; Zhang Z; Wang M; Xiao J; Wei X; Wang C
Cancer Biomark; 2017 Dec; 21(1):169-177. PubMed ID: 29036790
[TBL] [Abstract][Full Text] [Related]
24. [Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].
Li N; Jin ZL; Liu ZJ; Wang J; Li K
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):937-42. PubMed ID: 22340106
[TBL] [Abstract][Full Text] [Related]
25. METTL3 promotes non-small cell lung cancer (NSCLC) cell proliferation and colony formation in a m6A-YTHDF1 dependent way.
Dou X; Wang Z; Lu W; Miao L; Zhao Y
BMC Pulm Med; 2022 Aug; 22(1):324. PubMed ID: 36008805
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
27. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
Liu B; Wang R; Liu H
Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989
[TBL] [Abstract][Full Text] [Related]
28. Endostar combined with cisplatin inhibits tumor growth and lymphatic metastasis of lewis lung carcinoma xenografts in mice.
Dong XP; Xiao TH; Dong H; Jiang N; Zhao XG
Asian Pac J Cancer Prev; 2013; 14(5):3079-83. PubMed ID: 23803083
[TBL] [Abstract][Full Text] [Related]
29. Endostar (rh-endostatin) versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non-small cell lung cancer: A meta-analysis.
An J; Lv W
Thorac Cancer; 2018 May; 9(5):606-612. PubMed ID: 29575575
[TBL] [Abstract][Full Text] [Related]
30. Recombinant human endostatin, Endostar, enhances the effects of chemo-radiotherapy in a mouse cervical cancer xenograft model.
Jia Y; Liu M; Cao L; Zhao X; Wu J; Lu F; Li Y; He Y; Ren S; Ju Y; Wang Y; Li Z
Eur J Gynaecol Oncol; 2011; 32(3):316-24. PubMed ID: 21797125
[TBL] [Abstract][Full Text] [Related]
31. Methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit-induced long intergenic non-protein coding RNA 1833 N6-methyladenosine methylation promotes the non-small cell lung cancer progression via regulating heterogeneous nuclear ribonucleoprotein A2/B1 expression.
Li D; Fu Z; Dong C; Song Y
Bioengineered; 2022 Apr; 13(4):10493-10503. PubMed ID: 35441574
[TBL] [Abstract][Full Text] [Related]
32. Endostar down-regulates HIF-1 and VEGF expression and enhances the radioresponse to human lung adenocarcinoma cancer cells.
Zhang L; Ge W; Hu K; Zhang Y; Li C; Xu X; He D; Zhao Z; Zhang J; Jie F; Chen Y; Zheng Y
Mol Biol Rep; 2012 Jan; 39(1):89-95. PubMed ID: 21567206
[TBL] [Abstract][Full Text] [Related]
33. Super enhancer-LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1.
Shen Q; Zhou H; Zhang M; Wu R; Wang L; Wang Y; Chen J
J Clin Lab Anal; 2022 Jun; 36(6):e24460. PubMed ID: 35500152
[TBL] [Abstract][Full Text] [Related]
34. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
[TBL] [Abstract][Full Text] [Related]
35. Silence of fibronectin 1 increases cisplatin sensitivity of non-small cell lung cancer cell line.
Gao W; Liu Y; Qin R; Liu D; Feng Q
Biochem Biophys Res Commun; 2016 Jul; 476(1):35-41. PubMed ID: 27207836
[TBL] [Abstract][Full Text] [Related]
36. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
[TBL] [Abstract][Full Text] [Related]
37. The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.
Li X; Gu G; Soliman F; Sanders AJ; Wang X; Liu C
Chemotherapy; 2018; 63(4):214-219. PubMed ID: 30347389
[TBL] [Abstract][Full Text] [Related]
38. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p.
Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S
Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948
[TBL] [Abstract][Full Text] [Related]
39. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.
Han B; Xiu Q; Wang H; Shen J; Gu A; Luo Y; Bai C; Guo S; Liu W; Zhuang Z; Zhang Y; Zhao Y; Jiang L; Zhou J; Jin X
J Thorac Oncol; 2011 Jun; 6(6):1104-9. PubMed ID: 21532504
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy.
Zhou S; Zuo L; He X; Pi J; Jin J; Shi Y
Thorac Cancer; 2018 Nov; 9(11):1354-1360. PubMed ID: 30152052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
